Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact firstname.lastname@example.org.
SOURCE Decision Resources Group
Eli Lilly, the Sole Competitor in 2013, Will Be Joined by GE Healthcare, Piramal Enterprises and Navidea Biopharmaceuticals in the Next Few Years, According to Findings from Decision Resources Group
BURLINGTON, Mass., Feb. 12, 2014 /PRNewswire/ -- Decision Resources Group finds that the United States Alzheimer's imaging agent market will grow dramatically over the next 10 years. Currently, Eli Lilly's Amyvid, launched in June 2013, is the only Food and Drug Administration (FDA)-approved product available, but GE Healthcare, Piramal Enterprises and Navidea Biopharmaceuticals are all poised to launch products in the U.S. in the next few years.
Alzheimer's imaging agents are radiotracers capable of detecting beta-amyloid plaque in the brain, a pathological hallmark of Alzheimer's. Despite the high prevalence of Alzheimer's disease in the U.S., in 2013, this market was worth less than $3 million. There continues to be a lack of reimbursement for these procedures, which has severely restricted demand. In fact, many of the procedures that are performed are using free doses offered by Eli Lilly in order to spread awareness of the agent. Additionally, the benefits of the procedure remain under debate because there is currently no treatment for Alzheimer's disease itself.
"Going forward, a number of key events will dramatically reshape this market," said Decision Resources Group Analyst Jeremy Seath. "First, the Coverage with Evidence Development program will provide reimbursement for patients enrolled in approved clinical trials. Second, evidence from these trials is expected to result in a broad coverage decision a few years later, further improving access to these procedures and driving market growth. Finally, Eli Lilly's solanezumab, currently in Phase III clinical trials, is expected to gain approval in the U.S. and will represent the first disease-modifying therapeutic drug available. Because the drug targets the buildup of beta-amyloid plaque, its launch will significantly increase the value of the imaging agents, driving revenues."
Along with growing demand for these products, the expanding installed base of systems capable of performing Alzheimer's imaging agent procedures, including positron emission tomography/computed tomography (PET/CT) and positron emission tomography/magnetic resonance imaging (PET/MRI) systems, will improve accessibility of these procedures for patients.
Decision Resources Group's US Opportunities for Alzheimer's Imaging Agents 2014 report includes procedure, average selling price and revenue information, along with market drivers and limiters and a competitive landscape for Alzheimer's imaging agents in the United States.
About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information, and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.
All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.
For more information, contact:
Decision Resources Group
©2012 PR Newswire. All Rights Reserved.